IDH2R172 mutation in angioimmunoblastic T‐cell lymphoma: A retrospective multicenter case series.

Thirty-one patients (75%) received anthracycline/etoposide-based therapy (9 out of 31 were I IDH2 i SP I R172 i sp mutated) and 4 of them (4/31, 13%) were consolidated with autologous stem-cell transplantation (ASCT) in first complete remission (CR1); ASCT recipients were all I IDH2 i SP I WT i sp . Patients with I IDH2 i SP I WT i sp AITL achieved CR1 in 14/32 (44%), as opposed to 9/10 (90%) of I IDH2 i SP I R172 i sp patients ( I p i = .018). Thirty-two patients (32/42, 76%) were I IDH2 i SP I WT i sp , and 10 patients (10/42, 24%) were I IDH2 i SP I R172 i sp mutated. [Extracted from the article]